EUVIMEDEUVIMED entdecken
Crossref

Quantitative UHPLC–MS/MS Analysis of Gemcitabine and Its Active and Inactive Metabolites in Pig Plasma and Lung Tissue in Preparation of Locoregional Therapies for Non–Small Cell Lung Cancer

Erik Claes iD, Jeroen M H Hendriks, Thérèse S Lapperre, Johan Van Daele, Andreia Alves, Pieter Annaert, Stijn E Verleden

Journal of Mass Spectrometry · 2025

DOI: 10.1002/jms.5174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Mass Spectrometry, 2025. Verfasst von Erik Claes und 6 weiteren Autor:innen. Beteiligte Einrichtung: ASTARC (Antwerp Surgical Training, Anatomy and Research Centre), University of Antwerp, Wilrijk, Belgium. Hauptthemen laut MEDLINE: Deoxycytidine, Tandem Mass Spectrometry, Carcinoma, Non-Small-Cell Lung, Lung. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Kom op tegen Kanker, Collen Francqui Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gemcitabine (dFdC), an effective chemotherapeutic for non–small cell lung cancer (NSCLC), acts through its active metabolite, dFdCTP. Its current pharmacokinetics (PK) knowledge is based on intravenous infusion, which does not represent locoregional administration. In contrast, locoregional studies focus on dFdC, neglecting the role of dFdU (inactive) and dFdCTP, limiting our lung‐specific PK insights. Existing dFdCTP assays require lengthy runs and complex protocols, reducing their translatability for large‐scale studies. This study presents an ultra‐high‐performance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS) method to quantify dFdC, dFdU, and dFdCTP in pig lung tissue and plasma, improving gemcitabine's PK assessment following both systemic and locoregional therapies. A high‐throughput UHPLC–MS/MS method was developed and validated for the quantification of dFdC, dFdU, and dFdCTP in pig plasma and lung tissue. Protein precipitation was used, followed by chromatographic separation on a Luna Omega Polar C18 column with a 4‐min run time. Linearity was established over the ranges: 0.5–400.0 μg/mL (plasma) and 0.5–400.0 μg/g (lung tissue). It demonstrated robust accuracy, precision, and selectivity with minimal carryover and negligible matrix effects. Stability was confirmed for 4 h at 4°C, 40°C, and on the autosampler. The method's applicability was verified in study samples treated with a 30‐min intravenous gemcitabine (1.25 g/m 2 ) infusion. This UHPLC–MS/MS assay overcomes previous methodological limitations by reducing run time and simplifying sample preparation. Its robustness to quantify dFdC, dFdU, and dFdCTP in pig plasma and lung tissue has been confirmed, providing a valuable tool for future PK studies with locoregional therapies for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineTandem Mass SpectrometryCarcinoma, Non-Small-Cell LungLungAntimetabolites, AntineoplasticAnimalsGemcitabineChromatography, High Pressure LiquidSwineLung NeoplasmsReproducibility of ResultsLimit of DetectionLinear Models

Stichwörter der Autor:innen

UHPLC–MSdFdCdFdCTPdFdUgemcitabinelungplasma

Substanzen

GemcitabineDeoxycytidineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • ASTARC (Antwerp Surgical Training, Anatomy and Research Centre), University of Antwerp, Wilrijk, Belgium.
  • Department of Thoracic and Vascular Surgery, University Hospital Antwerp, Edegem, Belgium.
  • Department of Pulmonology, University Hospital Antwerp, Edegem, Belgium.
  • LEMP (Laboratory of Experimental Medicine and Pediatrics), University of Antwerp, Wilrijk, Belgium.
  • BioNotus CommV, Niel, Belgium.
  • Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

ORCID-Profile: Erik Claes

Förderung

  • Kom op tegen Kanker
  • Collen Francqui Foundation

Zitieren

APA

Claes, E., Hendriks, J. M. H., Lapperre, T. S., Van Daele, J., Alves, A., Annaert, P., & Verleden, S. E. (2025). Quantitative UHPLC–MS/MS Analysis of Gemcitabine and Its Active and Inactive Metabolites in Pig Plasma and Lung Tissue in Preparation of Locoregional Therapies for Non–Small Cell Lung Cancer. Journal of Mass Spectrometry. https://doi.org/10.1002/jms.5174

Vancouver

Claes E, Hendriks JMH, Lapperre TS, Van Daele J, Alves A, Annaert P, et al. Quantitative UHPLC–MS/MS Analysis of Gemcitabine and Its Active and Inactive Metabolites in Pig Plasma and Lung Tissue in Preparation of Locoregional Therapies for Non–Small Cell Lung Cancer. Journal of Mass Spectrometry. 2025. doi:10.1002/jms.5174

BibTeX
@article{Claes2025,
  author = {Claes, Erik and Hendriks, Jeroen M H and Lapperre, Thérèse S and Van Daele, Johan and Alves, Andreia and Annaert, Pieter and Verleden, Stijn E},
  title = {Quantitative UHPLC–MS/MS Analysis of Gemcitabine and Its Active and Inactive Metabolites in Pig Plasma and Lung Tissue in Preparation of Locoregional Therapies for Non–Small Cell Lung Cancer},
  journal = {Journal of Mass Spectrometry},
  year = {2025},
  doi = {10.1002/jms.5174}
}
Kostenlos starten →